• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

    11/8/24 9:33:38 AM ET
    $RIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RIGL alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    Rigel Pharmaceuticals Inc


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    766559702


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 766559702

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Invesco Ltd.
    98-0557567
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Bermuda

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 1,050,767
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 1,051,355
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,051,355
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.0%
    12. TYPE OF REPORTING PERSON

    HC, IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Rigel Pharmaceuticals Inc
    (b) Address of Issuer's Principal Executive Offices
    611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080
    Item 2.
    (a) Name of Person Filing
    Invesco Ltd. ("Invesco Ltd.")
    (b) Address of Principal Business Office or, if None, Residence
    1331 Spring Street NW, Suite 2500, Atlanta, GA 30309
    (c) Citizenship
    Bermuda
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    766559702
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    Invesco Ltd., in its capacity as a parent holding company to its investment advisers, may be deemed to beneficially own 1,051,355 shares of the Issuer which are held of record by clients of Invesco Ltd.
    (b) Percent of Class:
    6.0%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 1,050,767
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 1,051,355
    (iv) shared power to dispose or to direct the disposition of 0
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Invesco Capital Management LLC is a subsidiary of Invesco Ltd. and it advises the Invesco Dorsey Wright SmallCap Momentum ETF which owns 5.93% of the security reported herein. However, no one individual has greater than 5% economic ownership. The shareholders of the Fund have the right to receive or the power to direct the receipt of dividends and proceeds from the sale of securities listed above.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Invesco Capital Management LLC
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Invesco Ltd.
    By: /s/ Robert R. Leveille
    Date: November 08, 2024
    Name: Robert R. Leveille
    Title: Global Head of Compliance

    Get the next $RIGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RIGL

    DatePrice TargetRatingAnalyst
    4/3/2023$2.00Neutral
    Piper Sandler
    6/9/2022Buy → Neutral
    Citigroup
    6/8/2022$7.00 → $1.00Overweight → Neutral
    Piper Sandler
    6/8/2022$6.00 → $1.00Overweight → Neutral
    Cantor Fitzgerald
    3/23/2022$4.00Neutral
    B. Riley Securities
    More analyst ratings

    $RIGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rigel to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 12:50 p.m. ET in New York, NY. To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads. About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotec

      5/28/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress

      Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors  Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AMLSOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced seven upcoming poster presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) 2025 Congress. The ASCO Annual Meeting is being held in Chicago, Illinois and virtually from May 30 to June 3, 2025. The EHA2025 Congress is

      5/22/25 5:20:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Wasman Jane was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:41 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ali-Jackson Kamil was granted 2,500 shares, increasing direct ownership by 36% to 9,375 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:31 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4)

      4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)

      5/28/25 5:27:19 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

      SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy.   "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm

      3/10/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp

      3/12/24 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $RIGL
    SEC Filings

    See more
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/23/25 4:01:19 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:23:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Rigel Pharmaceuticals Inc.

      10-Q - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)

      5/6/25 4:05:42 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Financials

    Live finance-specific insights

    See more
    • Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

      First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on

      5/6/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

      SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's webs

      4/29/25 8:05:00 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product sales of $8.1 million 2024 total revenue of approximately $179.3 million, which includes TAVALISSE® net product sales of $104.8 million, REZLIDHIA® net product sales of $23.0 million and GAVRETO® net product sales of $17.1 millionR289 granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS and Orphan Drug designation for the treatment of MDS by the FDA2025 Outlook: Total revenue of approximately $200 to $210 millionConference call and webcast sch

      3/4/25 4:01:00 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler resumed coverage on Rigel Pharma with a new price target

      Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00

      4/3/23 9:11:21 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Citigroup

      Citigroup downgraded Rigel Pharma from Buy to Neutral

      6/9/22 7:22:28 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rigel Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Rigel Pharma from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously

      6/8/22 1:49:43 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 5:18:08 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rigel Pharmaceuticals Inc.

      SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/14/24 3:33:13 PM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Rigel Pharmaceuticals Inc.

      SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)

      11/8/24 9:33:38 AM ET
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care